HeartFlow(HTFL)
Focus: HeartFlow is a public SAN FRANCISCO-based biotech focused on AI-enabled coronary artery disease assessment via non-invasive imaging (FFRCT technology). The company operates in the $X billion cardiovascular diagnostics market with a lean commercial model.
Profile data last refreshed 6h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
101+24 this month
Hot — 64 jobs added in 30d
Net +24 (64 new, 40 removed). Aggressive expansion phase.
Should You Work at HeartFlow?
AI assessmentBest fit for technologists, commercial operators, and clinicians betting on AI-diagnostics disruption in cardiology; not ideal for pharma career-path traditionalists.
Why Work Here
- High R&D intensity (41%) and 20 active clinical programs signal deep scientific investment in cardio-oncology and metabolic disease
- Commercial hiring surge (25 of 61 open roles) indicates aggressive market expansion post-IPO with revenue growing to $87M in FY2025
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
24 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$87M
Pipeline & Clinical Trials
Heartflow Analysis
CAD - Coronary Artery DiseaseClinical Trials (2)
NCT07834372REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
N/AHelp build intelligence for HeartFlow
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.